Best Biologics / mAb CDMOs in United States
· updated as new inspection, certificate, and trial data enters the platform
18
CDMOs tracked
18
Fully scored
13
With FDA records
36
FDA inspections
106
EMA/MHRA GMP certs
Biologics CDMOs manufacture monoclonal antibodies, fusion proteins, and other large molecules in mammalian (typically CHO) cell culture. It is the largest and most mature segment of contract manufacturing, spanning early clinical supply through multi-thousand-litre commercial production.
Selecting a biologics CDMO turns on bioreactor scale and modality fit (mAb, bispecific, fusion protein), titer and cell-line strategy, fill-finish, and — above all — a clean regulatory record at commercial scale. The rankings below score each CDMO on FDA inspection history, EMA/MHRA GMP certification, clinical-program activity, and capacity.
FDA inspection outcomes across these CDMOs: 13 NAI (no action), 22 VAI (voluntary action), 1 OAI (official action). Leading inspection & GMP sites: United States (26), UNITED KINGDOM (25), Denmark (17), Ireland (13), Spain (10).
Last updated 2026-09-15. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
PC
Pfizer CentreOne
Kalamazoo, MI · McPherson, KS
|
91.5 | 100.0 | 4 insp · 17 GMP | — | 366 programs |
| 2 |
MK
Merck KGaA / MilliporeSigma (CDMO)
Darmstadt, DE · St. Louis, MO
|
81.8 | 98.7 | 2 insp · 2 GMP | — | 22 programs |
| 3 |
FD
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
|
84.8 | 100.0 | 0 insp · 23 GMP | 0 programs | |
| 4 |
AJ
Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
|
83.5 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 5 |
PR
Piramal Pharma Solutions
Lexington, KY · Riverview, MI · Ahmedabad, IN
|
83.3 | 95.0 | 5 insp · 13 GMP | — | 0 programs |
| 6 |
LB
Lotte Biologics
Incheon, KR · Syracuse, NY
|
81.6 | 100.0 | 1 insp · 0 GMP | — | 0 programs |
| 7 |
EF
Eurofins CDMO
Planegg, DE · San Diego, CA
|
81.6 | 100.0 | 5 insp · 0 GMP | — | 0 programs |
| 8 |
EK
Evonik Health Care
Birmingham, AL · Vancouver, BC
|
81.5 | 99.8 | 2 insp · 2 GMP | — | 0 programs |
| 9 |
CD
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
|
81.1 | 98.9 | 4 insp · 10 GMP | — | 0 programs |
| 10 |
AV
Avid Bioservices
Tustin, CA
|
80.8 | 100.0 | 1 insp · 0 GMP | — | 0 programs |
| 11 |
NW
Northway Biotech
Vilnius, LT; Waltham (MA), USA
|
80.8 | 100.0 | 0 insp · 8 GMP | Available | 0 programs |
| 12 |
BR
BioReliance (Merck)
Glasgow, UK · Rockville, MD
|
80.2 | 97.1 | 4 insp · 8 GMP | — | 0 programs |
| 13 |
CRA
Curia (RNA/Advanced)
Albany, NY · Albuquerque, NM
|
79.4 | 99.9 | 2 insp · 18 GMP | — | 0 programs |
| 14 |
Cytovance Biologics
Oklahoma City, OK
|
78.6 | 98.1 | 1 insp · 0 GMP | Available | 0 programs |
| 15 |
AF
Afton Scientific
Charlottesville, VA
|
76.8 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 16 |
KD
Kindeva Drug Delivery
Woodbury, MN
|
76.0 | 98.2 | 2 insp · 3 GMP | — | 0 programs |
| 17 |
GM
Grand River Aseptic Manufacturing
Grand Rapids, MI
|
66.6 | 78.1 | 3 insp · 0 GMP | — | 0 programs |
| 18 |
CU
Culture Biosciences
South San Francisco, CA
|
56.5 | — | — | — | 0 programs |
What to evaluate in a Biologics / mAb CDMO
Scale & bioreactor fit
Match validated bioreactor scale (from a few hundred litres clinical to 2,000L+ commercial) and single-use vs stainless to your dose and indication. Confirm titer expectations for your construct.
Cell line & process development
Ask whether the CDMO offers its own expression platform/cell line or works from yours, and how process development and tech transfer are handled.
Regulatory track record
Biologics programs heading to BLA/MAA need a strong commercial-scale inspection history. Cross-check FDA 483s, warning letters, and EMA/MHRA GMP coverage — all shown above.
Drug substance to drug product
Confirm whether the CDMO covers fill-finish and formulation in-house or coordinates a separate site, which affects timelines and comparability.
FDA jurisdiction — how the ranking scores US-based CDMOs
The Signal Score's Quality Compliance pillar (35% of the composite) is dominated by FDA inspection data for US-based CDMOs: Establishment Inspection Report classifications (NAI, VAI, OAI), Form 483 observation counts, and Warning Letter history. For a CDMO whose primary facility footprint is US, this pillar carries direct weight — an inspection on the site slated for a sponsor's program applies without translation. For CDMOs with mixed US + international facility footprint, the ranking reflects the composite regulatory posture; sponsors evaluating for a specific program should verify inspection history on the exact US site under consideration via that CDMO's profile page.
Which US CDMOs also cover EU and UK regulatory geographies?
Many top-tier US-based CDMOs maintain EU (EMA) and UK (MHRA) GMP certification for facilities used to supply EU and UK trials or commercial markets. The Signal Score's Quality Compliance pillar includes EMA + MHRA certificate density as a component — a US-headquartered CDMO with dense EU/UK certificates typically ranks higher on this pillar than a US-only competitor. Sponsors running dual-jurisdiction programs should cross-check the individual CDMO profile pages for specific certificate coverage; the Europe region ranking surfaces CDMOs that also appear in the European jurisdiction ranking, indicating multi-region regulatory posture.
How CDMO Signal identifies US manufacturing presence
Region attribution is derived from each CDMO's declared facility locations in our directory. A CDMO's facility list is validated against corporate filings, press releases, and — where public — the FDA facility registration (FEI number lookups). Region matching is done at the country level: a US state name or two-letter abbreviation in the facility list places the CDMO in the US region. CDMOs with US + international sites appear in every applicable region ranking, which reflects operational reality — such a CDMO is a legitimate candidate for programs in any of those jurisdictions.
Biologics / mAb CDMOs — Frequently Asked Questions
Who are the top Biologics / mAb CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Biologics / mAb CDMOs include Pfizer CentreOne, Merck KGaA / MilliporeSigma (CDMO), FUJIFILM Diosynth Biotechnologies. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Biologics / mAb CDMOs have FDA inspection records?
CDMO Signal tracks 13 Biologics / mAb CDMOs with FDA inspection records and 106 EMA/MHRA GMP certificates across the group.
What should I look for in a biologics CDMO?
Match bioreactor scale and modality (mAb, bispecific, fusion protein) to your program, confirm cell-line and process-development support, and prioritize a clean FDA and EMA/MHRA record at the scale you'll commercialize at.
What is the difference between a biologics CDMO and a cell or gene therapy CDMO?
Biologics CDMOs make large molecules (antibodies, proteins) in bioreactors at litre-to-thousands-of-litre scale. Cell and gene therapy CDMOs make living cells or viral vectors in much smaller, often per-patient batches under different containment and analytics.
Related modalities